Rhonda L Bitting
Instructor in the Department of Medicine
Current Appointments & Affiliations
- Instructor in the Department of Medicine, Medicine, Medical Oncology, Medicine 2020
Contact Information
- 905 S Lasalle St, Rm 2052, Durham, NC 27710
- DUMC Box 103861, Durham, NC 27710
-
rhonda.bitting@duke.edu
(919) 613-1887
- Background
-
Education, Training, & Certifications
- Fellowship, Hematology And Oncology, Duke University 2009 - 2012
- Residency, Internal Medicine, University of California, School of Medicine 2006 - 2008
- M.D., Vanderbilt University 2005
-
Medical Licensure
- 2009-01126. North Carolina. 2020
-
Duke Appointment History
- Medical Instructor in the Department of Medicine, Medicine, Medical Oncology, Medicine 2012 - 2013
- Expertise
-
Subject Headings
- Research
-
Selected Grants
-
External Relationships
- Durham VA Medical Center
- Publications & Artistic Works
-
Selected Publications
-
Academic Articles
-
Bitting, Rhonda L., Michael Goodman, and Daniel J. George. “Racial Disparity in Response to Prostate Cancer Systemic Therapies.” Curr Oncol Rep 22, no. 9 (July 23, 2020): 96. https://doi.org/10.1007/s11912-020-00966-z.Full Text Link to Item
-
Bitting, Rhonda L., Patrick Healy, Daniel J. George, Monika Anand, Sung Kim, Tina Mayer, Carol Winters, et al. “Phase II Trial of Enzalutamide and Androgen Deprivation Therapy with Salvage Radiation in Men with High-risk Prostate-specific Antigen Recurrent Prostate Cancer: The STREAM Trial.” Eur Urol Oncol, February 13, 2020. https://doi.org/10.1016/j.euo.2020.01.005.Full Text Link to Item
-
Peak, Taylor C., Gati K. Panigrahi, Prakash P. Praharaj, Yixin Su, Lihong Shi, Jacqueline Chyr, José Rivera-Chávez, et al. “Syntaxin 6-mediated exosome secretion regulates enzalutamide resistance in prostate cancer.” Mol Carcinog 59, no. 1 (January 2020): 62–72. https://doi.org/10.1002/mc.23129.Full Text Link to Item
-
Praharaj, Prakash P., Sujit K. Bhutia, Sunitha Nagrath, Rhonda L. Bitting, and Gagan Deep. “Circulating tumor cell-derived organoids: Current challenges and promises in medical research and precision medicine.” Biochim Biophys Acta Rev Cancer 1869, no. 2 (April 2018): 117–27. https://doi.org/10.1016/j.bbcan.2017.12.005.Full Text Link to Item
-
Yang, M., M. E. Forbes, R. L. Bitting, S. S. O’Neill, P. -. C. Chou, U. Topaloglu, L. D. Miller, et al. “Incorporating blood-based liquid biopsy information into cancer staging: time for a TNMB system?” Ann Oncol 29, no. 2 (February 1, 2018): 311–23. https://doi.org/10.1093/annonc/mdx766.Full Text Link to Item
-
Logue, Jennifer M., Bahram Kiani, and Rhonda L. Bitting. “Pazopanib and Statin-Induced Rhabdomyolysis.” Case Rep Oncol 10, no. 3 (September 2017): 954–57. https://doi.org/10.1159/000481659.Full Text Link to Item
-
Yang, Meng, Umit Topaloglu, W Jeffrey Petty, Matthew Pagni, Kristie L. Foley, Stefan C. Grant, Mac Robinson, et al. “Circulating mutational portrait of cancer: manifestation of aggressive clonal events in both early and late stages.” J Hematol Oncol 10, no. 1 (May 4, 2017): 100. https://doi.org/10.1186/s13045-017-0468-1.Full Text Link to Item
-
Gupta, Santosh, Jing Li, Gabor Kemeny, Rhonda L. Bitting, Joshua Beaver, Jason A. Somarelli, Kathryn E. Ware, Simon Gregory, and Andrew J. Armstrong. “Whole Genomic Copy Number Alterations in Circulating Tumor Cells from Men with Abiraterone or Enzalutamide-Resistant Metastatic Castration-Resistant Prostate Cancer.” Clin Cancer Res 23, no. 5 (March 1, 2017): 1346–57. https://doi.org/10.1158/1078-0432.CCR-16-1211.Full Text Link to Item
-
Jackson, Gregory, Nora Fino, and Rhonda L. Bitting. “Clinical Characteristics of Patients With Renal Cell Carcinoma and Metastasis to the Thyroid Gland.” Clin Med Insights Oncol 11 (2017): 1179554917743981. https://doi.org/10.1177/1179554917743981.Full Text Link to Item
-
Kytola, Ville, Umit Topaloglu, Lance D. Miller, Rhonda L. Bitting, Michael M. Goodman, Ralph B. D Agostino, Rodwige J. Desnoyers, et al. “Mutational Landscapes of Smoking-Related Cancers in Caucasians and African Americans: Precision Oncology Perspectives at Wake Forest Baptist Comprehensive Cancer Center.” Theranostics 7, no. 11 (2017): 2914–23. https://doi.org/10.7150/thno.20355.Full Text Link to Item
-
Davis, Kristen, Sarah Wood, Emily Dill, Yuri Fesko, Rhonda L. Bitting, Michael R. Harrison, Andrew J. Armstrong, Judd W. Moul, and Daniel J. George. “Optimizing the efficiency and quality of sipuleucel-T delivery in an academic institution.” Clin J Oncol Nurs 19, no. 3 (June 2015): 297–303. https://doi.org/10.1188/15.CJON.297-303.Full Text Link to Item
-
Bitting, Rhonda L., Patrick Healy, Susan Halabi, Daniel J. George, Michael Goodin, and Andrew J. Armstrong. “Clinical phenotypes associated with circulating tumor cell enumeration in metastatic castration-resistant prostate cancer.” Urol Oncol 33, no. 3 (March 2015): 110.e1-110.e9. https://doi.org/10.1016/j.urolonc.2014.09.002.Full Text Link to Item
-
Bitting, Rhonda L., Daneen Schaeffer, Jason A. Somarelli, Mariano A. Garcia-Blanco, and Andrew J. Armstrong. “The role of epithelial plasticity in prostate cancer dissemination and treatment resistance.” Cancer Metastasis Rev 33, no. 2–3 (September 2014): 441–68. https://doi.org/10.1007/s10555-013-9483-z.Full Text Link to Item
-
Bitting, Rhonda L., Patrick Healy, Patricia A. Creel, James Turnbull, Karla Morris, Sarah Yenser Wood, Herbert I. Hurwitz, et al. “A phase Ib study of combined VEGFR and mTOR inhibition with vatalanib and everolimus in patients with advanced renal cell carcinoma.” Clin Genitourin Cancer 12, no. 4 (August 2014): 241–50. https://doi.org/10.1016/j.clgc.2013.11.020.Full Text Link to Item
-
Armstrong, Andrew J., Tong Shen, Susan Halabi, Gabor Kemeny, Rhonda L. Bitting, Patricia Kartcheske, Elizabeth Embree, et al. “A phase II trial of temsirolimus in men with castration-resistant metastatic prostate cancer.” Clin Genitourin Cancer 11, no. 4 (December 2013): 397–406. https://doi.org/10.1016/j.clgc.2013.05.007.Full Text Link to Item
-
Bitting, Rhonda L., Rengasamy Boominathan, Chandra Rao, Gabor Kemeny, Brad Foulk, Mariano A. Garcia-Blanco, Mark Connelly, and Andrew J. Armstrong. “Development of a method to isolate circulating tumor cells using mesenchymal-based capture.” Methods 64, no. 2 (December 1, 2013): 129–36. https://doi.org/10.1016/j.ymeth.2013.06.034.Full Text Link to Item
-
Bitting, R. L., P. K. Marcom, and A. Kamal. “Identifying benchmarks for ASCO's "Choosing Wisely" measures that address low-value imaging in early-stage prostate and breast cancer.” J Clin Oncol 31, no. 31_suppl (November 2013): 194. https://doi.org/10.1200/jco.2013.31.31_suppl.194.Full Text Link to Item
-
Noonan, K. L., S. North, R. L. Bitting, A. J. Armstrong, S. L. Ellard, and K. N. Chi. “Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide.” Ann Oncol 24, no. 7 (July 2013): 1802–7. https://doi.org/10.1093/annonc/mdt138.Full Text Link to Item
-
Bitting, Rhonda L., and Andrew J. Armstrong. “Targeting the PI3K/Akt/mTOR pathway in castration-resistant prostate cancer.” Endocr Relat Cancer 20, no. 3 (June 2013): R83–99. https://doi.org/10.1530/ERC-12-0394.Full Text Link to Item
-
Bitting, Rhonda L., and Andrew J. Armstrong. “Potential predictive biomarkers for individualizing treatment for men with castration-resistant prostate cancer.” Cancer J 19, no. 1 (January 2013): 25–33. https://doi.org/10.1097/PPO.0b013e31827e0b9c.Full Text Link to Item
-
Bitting, Rhonda L., and Andrew J. Armstrong. “Prognostic, predictive, and surrogate factors for individualizing treatment for men with castration-resistant prostate cancer.” Am Soc Clin Oncol Educ Book, 2012, 292–97. https://doi.org/10.14694/EdBook_AM.2012.32.24.Full Text Link to Item
-
Armstrong, Andrew J., Matthew S. Marengo, Sebastian Oltean, Gabor Kemeny, Rhonda L. Bitting, James D. Turnbull, Christina I. Herold, Paul K. Marcom, Daniel J. George, and Mariano A. Garcia-Blanco. “Circulating tumor cells from patients with advanced prostate and breast cancer display both epithelial and mesenchymal markers.” Mol Cancer Res 9, no. 8 (August 2011): 997–1007. https://doi.org/10.1158/1541-7786.MCR-10-0490.Full Text Link to Item
-
Bitting, Rhonda L., John Madden, and Andrew J. Armstrong. “Therapy for non-clear cell histologies in renal cancer.” Curr Clin Pharmacol 6, no. 3 (August 2011): 169–80. https://doi.org/10.2174/157488411797189460.Full Text Link to Item
-
Bitting, Rhonda L., Andrew J. Armstrong, and Daniel J. George. “Management Options in Advanced Prostate Cancer: What is the Role for Sipuleucel-T?” Clin Med Insights Oncol 5 (2011): 325–32. https://doi.org/10.4137/CMO.S5977.Full Text Link to Item
-
Bitting, Rhonda L., Stephen Bent, Yongmei Li, and Jeffrey Kohlwes. “The prognosis and treatment of acquired hemophilia: a systematic review and meta-analysis.” Blood Coagul Fibrinolysis 20, no. 7 (October 2009): 517–23. https://doi.org/10.1097/MBC.0b013e32832ca388.Full Text Link to Item
-
Powers, James S., Leena Choi, Rhonda Bitting, Nitin Gupta, and Maciej Buchowski. “Rapid measurement of total body water to facilitate clinical decision making in hospitalized elderly patients.” J Gerontol a Biol Sci Med Sci 64, no. 6 (June 2009): 664–69. https://doi.org/10.1093/gerona/glp018.Full Text Link to Item
-
Engelhardt, Brian G., Derek W. Holland, Stephen J. Brandt, Wichai Chinratanalab, Stacey A. Goodman, John P. Greer, Madan H. Jagasia, et al. “High-dose chemotherapy followed by autologous stem cell transplantation for relapsed or refractory Hodgkin lymphoma: prognostic features and outcomes.” Leuk Lymphoma 48, no. 9 (September 2007): 1728–35. https://doi.org/10.1080/10428190701534374.Full Text Link to Item
-
Dhar, Sumeer, Rhonda L. Bitting, Svetlana N. Rylova, Paul J. Jansen, Ellen Lockhart, Dwight D. Koeberl, Andrea Amalfitano, and Rose-Mary N. Boustany. “Flupirtine blocks apoptosis in batten patient lymphoblasts and in human postmitotic CLN3- and CLN2-deficient neurons.” Ann Neurol 51, no. 4 (April 2002): 448–66. https://doi.org/10.1002/ana.10143.Full Text Link to Item
-
-
Book Sections
-
Lash, T., and R. L. Bitting. “Novel therapies in castration-resistant prostate cancer.” In Managing Metastatic Prostate Cancer In Your Urological Oncology Practice, 259–69, 2016. https://doi.org/10.1007/978-3-319-31341-2_15.Full Text
-
-
Conference Papers
-
Hanson, Erik D., Jackson L. Carver, Alexander Lucas, Michael Bass, Mohamdod Alzer, Young Whang, Michael Harrison, Matthew I. Milowsky, Rhonda L. Bitting, and Claudio L. Battaglini. “High Adherence To Home-Based Exercise Improves Muscle Strength And Cardiorespiratory Fitness With Advanced Prostate Cancer.” In Medicine & Science in Sports & Exercise, 51:6–7. Ovid Technologies (Wolters Kluwer Health), 2019. https://doi.org/10.1249/01.mss.0000560506.05468.17.Full Text
-
Zhang, Tian, Bridget F. Koontz, Scott T. Tagawa, Himanshu Nagar, Rhonda L. Bitting, Bart Frizzell, Julia Rasmussen, et al. “A phase II Salvage Trial of AR Inhibition with ADT and Apalutamide with Radiation therapy followed by docetaxel in men with PSA recurrent prostate cancer (PC) after radical prostatectomy (STARTAR).” In Journal of Clinical Oncology, 37:TPS5097–TPS5097. American Society of Clinical Oncology (ASCO), 2019. https://doi.org/10.1200/jco.2019.37.15_suppl.tps5097.Full Text
-
Armstrong, Andrew J., Rhonda L. Bitting, Patrick Healy, Daniel J. George, Sung Kim, Tina M. Mayer, Carolyn Winters, et al. “Phase II trial enzalutamide and androgen deprivation therapy (ADT) with salvage radiation in men with high-risk PSA recurrent prostate cancer (PC): The STREAM trial.” In Journal of Clinical Oncology, 37:29–29. American Society of Clinical Oncology (ASCO), 2019. https://doi.org/10.1200/jco.2019.37.7_suppl.29.Full Text
-
George, Daniel J., Elisabeth I. Heath, A Oliver Sartor, Guru Sonpavde, William R. Berry, Patrick Healy, Carolyn Winters, et al. “Abi Race: A prospective, multicenter study of black (B) and white (W) patients (pts) with metastatic castrate resistant prostate cancer (mCRPC) treated with abiraterone acetate and prednisone (AAP).” In Journal of Clinical Oncology, Vol. 36. AMER SOC CLINICAL ONCOLOGY, 2018.Link to Item
-
Bitting, Rhonda L., Janet A. Tooze, William J. Petty, Stefan C. Grant, Rodwige J. Desnoyers, Alexandra Thomas, Christopher Y. Thomas, et al. “Phase I study of muscadine grape extract in advanced malignancy.” In Journal of Clinical Oncology, 36:e14548–e14548. American Society of Clinical Oncology (ASCO), 2018. https://doi.org/10.1200/jco.2018.36.15_suppl.e14548.Full Text
-
Sanborn, Rachel E., Michael J. Pishvaian, Margaret K. Callahan, Amy M. Weise, Branimir I. Sikic, Osama E. Rahma, Daniel C. Cho, et al. “Anti-CD27 agonist antibody varlilumab (varli) with nivolumab (nivo) for colorectal (CRC) and ovarian (OVA) cancer: Phase (Ph) 1/2 clinical trial results.” In Journal of Clinical Oncology, 36:3001–3001. American Society of Clinical Oncology (ASCO), 2018. https://doi.org/10.1200/jco.2018.36.15_suppl.3001.Full Text
-
Armstrong, Andrew J., Susan Halabi, Patrick Healy, Joshi J. Alumkal, Carolyn Winters, Julie Kephart, Rhonda L. Bitting, et al. “Phase II trial of the PI3 kinase inhibitor buparlisib (BKM-120) with or without enzalutamide in men with metastatic castration resistant prostate cancer.” In Eur J Cancer, 81:228–36, 2017. https://doi.org/10.1016/j.ejca.2017.02.030.Full Text Link to Item
-
Peak, Taylor C., Nicole P. Kasica, Gati K. Panigrahi, Sierra L. Patterson, Ravi Singh, Ashok K. Hemal, Rhonda L. Bitting, and Gagan Deep. “Abstract 3187: Role of exosome secretion in the survival of enzalutamide-resistant prostate cancer cells: Syntaxin 6 as a novel therapeutic target.” In Experimental and Molecular Therapeutics. American Association for Cancer Research, 2017. https://doi.org/10.1158/1538-7445.am2017-3187.Full Text
-
Piha-Paul, Sarina Anne, Cinta Hierro, Valentina Boni, Victor Moreno, Noah M. Hahn, Rhonda L. Bitting, Todd Michael Bauer, et al. “A phase 1, multicenter, dose-escalation study of PRN1371, an irreversible covalent FGFR1-4 kinase inhibitor, in patients with advanced solid tumors, followed by expansion cohorts in patients with FGFR genetic alterations.” In Journal of Clinical Oncology, 35:TPS2616–TPS2616. American Society of Clinical Oncology (ASCO), 2017. https://doi.org/10.1200/jco.2017.35.15_suppl.tps2616.Full Text
-
Salzberg, Marc Oliver, Pierre Triozzi, Mitra Kooshki, Angela Tatiana Alistar, Rhonda Lynn Bitting, Joyce Fenstermaker, Guenther Lametschwandtner, and Hans Loibner. “Adoptive cellular immunotherapy with APN401, autologous Cbl-b-silenced peripheral blood mononuclear cells, in patients with solid tumors.” In Journal of Clinical Oncology, 34:e14541–e14541. American Society of Clinical Oncology (ASCO), 2016. https://doi.org/10.1200/jco.2016.34.15_suppl.e14541.Full Text
-
Li, Jing, Joshua Beaver, Rhonda Lynn Bitting, Simon Gregory, and Andrew J. Armstrong. “Genomic analysis of circulating tumor cells (CTCs) from men with metastatic castration resistant prostate cancer (mCRPC) in the context of enzalutamide therapy.” In Journal of Clinical Oncology, 33:5042–5042. American Society of Clinical Oncology (ASCO), 2015. https://doi.org/10.1200/jco.2015.33.15_suppl.5042.Full Text
-
Li, Jing, Joshua Beaver, Rhonda Lynn Bitting, Simon Gregory, and Andrew J. Armstrong. “Genomic analysis of circulating tumor cells (CTCs) from men with metastatic castration resistant prostate cancer (mCRPC) in the context of enzalutamide therapy.” In Journal of Clinical Oncology, 32:e16059–e16059. American Society of Clinical Oncology (ASCO), 2014. https://doi.org/10.1200/jco.2014.32.15_suppl.e16059.Full Text
-
Armstrong, Andrew J., Jing Li, Joshua Beaver, Rhonda Lynn Bitting, and Simon Gregory. “Genomic analysis of circulating tumor cells (CTCs) from men with metastatic castration resistant prostate cancer (mCRPC) in the context of enzalutamide therapy.” In Journal of Clinical Oncology, 32:65–65. American Society of Clinical Oncology (ASCO), 2014. https://doi.org/10.1200/jco.2014.32.4_suppl.65.Full Text
-
Armstrong, Andrew J., Rhonda Lynn Bitting, Gabor Kemeny, and Daniel J. George. “Evidence for circulating tumor cell (CTC) alkaline phosphatase (AP) expression in men with bone-metastatic castration-resistant prostate cancer (CRPC) during abiraterone acetate treatment.” In Journal of Clinical Oncology, 32:178–178. American Society of Clinical Oncology (ASCO), 2014. https://doi.org/10.1200/jco.2014.32.4_suppl.178.Full Text
-
Power, Steve, Rhonda Lynn Bitting, P Kelly Marcom, and Arif Kamal. “Identifying benchmarks for ASCO's "Choosing Wisely" measures that address low-value imaging in early-stage prostate and breast cancer.” In Journal of Clinical Oncology, Vol. 31. AMER SOC CLINICAL ONCOLOGY, 2013. https://doi.org/10.1200/jco.2013.31.31_suppl.194.Full Text Link to Item
-
Bitting, Rhonda Lynn, Patrick Healy, Susan Halabi, Daniel J. George, Jung Hyun Ko, and Andrew J. Armstrong. “Evaluation of clinical phenotype, survival, and circulating tumor cell (CTC) enumeration in men with metastatic castration-resistant prostate cancer (mCRPC).” In Journal of Clinical Oncology, Vol. 31. AMER SOC CLINICAL ONCOLOGY, 2013.Link to Item
-
Armstrong, Andrew J., Tong Shen, Susan Halabi, Gabor Kemeny, Rhonda Lynn Bitting, Patricia Kartcheske, Elizabeth Embree, et al. “A phase II trial of temsirolimus in men with castration-resistant metastatic prostate cancer.” In Journal of Clinical Oncology, 31:105–105. American Society of Clinical Oncology (ASCO), 2013. https://doi.org/10.1200/jco.2013.31.6_suppl.105.Full Text
-
Bitting, Rhonda Lynn, Rengasamy Boominathan, Chandra Rao, Elizabeth Embree, Daniel J. George, Mark C. Connelly, Gabor Kemeny, Mariano Garcia-Blanco, and Andrew J. Armstrong. “Isolation of circulating tumor cells using a novel EMT-based capture method.” In Journal of Clinical Oncology, Vol. 30. AMER SOC CLINICAL ONCOLOGY, 2012.Link to Item
-
-
Some information on this profile has been compiled automatically from Duke databases and external sources. (Our About page explains how this works.) If you see a problem with the information, please write to Scholars@Duke and let us know. We will reply promptly.